Gilead Sciences and partner Arcellx reported pivotal-stage results for anito-cel in multiple myeloma showing deep, durable responses with acceptable safety. In the analysis of 117 patients presented at ASH, companies said 96% of participants showed a tumor response and 74% reached complete remission, signaling potential best-in-class positioning. The data arrive as Gilead prepares to challenge existing myeloma CAR‑T therapies and address waning sales of its older blood-cancer assets. Management framed the results as critical to commercial uptake and broader CAR‑T adoption.